BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35371002)

  • 21. Prognostic factors and treatment outcomes for patients with stage II extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract.
    Fang H; Jin J; Wang WH; Wang SL; Zhou LQ; Li YX
    Leuk Lymphoma; 2014 Aug; 55(8):1832-7. PubMed ID: 24144309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment 14-3-3 epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginase-based chemotherapy.
    Qiu Y; Zhou Z; Li Z; Lu L; Li L; Li X; Wang X; Zhang M
    Proteomics Clin Appl; 2017 Mar; 11(3-4):. PubMed ID: 27774748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
    Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
    Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A five
    Vittayawacharin P; Khuhapinant A
    Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
    Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
    Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
    Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
    Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T-cell lymphoma.
    Shen Z; Chen X; Sun C; Lu T; Shi Y; Zhang H; Ye J; Wang L; Zhu T; Miao Y; Zhang X; Wang L; Cai G; Sang W
    Cancer Med; 2023 Dec; 12(23):21138-21147. PubMed ID: 37902266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
    Wu W; Chen X; Li N; Luo Q; Zou L
    Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
    de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
    Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
    Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
    Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
    Chen B; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Wu T; Qi SN; Yang Y; Liu X; Li YX
    Cancer Med; 2018 Dec; 7(12):5952-5961. PubMed ID: 30358175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma.
    Sun Z; Wan W; Zhang X; Zhang L; Li X; Li L; Wang X; Nan F; Yu H; Chang Y; Yan J; Li Z; Cui F; Ge J; XiaXu YD; Xu X; Fu X; Zhang M
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3449-3459. PubMed ID: 35857124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotyping of peripheral blood lymphocytes by flow cytometry reveals Th cell as a potential prognostic biomarker for extranodal NK/T-cell lymphoma.
    Qi F; Wei Y; Wu M; Sun Y; Xie Y; Lin N; Liu W; Wang W; Song Y; Zhu J
    Ann Hematol; 2024 May; 103(5):1643-1653. PubMed ID: 38191717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
    Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
    Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
    Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents.
    Wang GN; Zhao WG; Zhang XD; Jian XY; Zhang CL; Zhang MZ; Li WC
    Sci Rep; 2022 May; 12(1):7118. PubMed ID: 35504960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics, Prognostic Factors, and Survival of Patients with NK/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center Experience.
    Liu ZL; Bi XW; Zhang XW; Lei DX; Liu PP; Yang H; Gao Y; Jiang YX; Jiang WQ; Xia Y
    Cancer Res Treat; 2019 Oct; 51(4):1557-1567. PubMed ID: 30971067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma.
    Hui Y; Gao Y; Li J; Kong Q; Duan Y; Liu H; Liu F; Sang H
    Ann Hematol; 2024 Apr; 103(4):1285-1292. PubMed ID: 38095656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
    Lin N; Ku W; Song Y; Zhu J; Lu Z
    Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.